Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure

Fang,Zhihua; Yin,Xiaoguang; Wang,Jianzhong; Tian,Na; Ao,Qiang; Gu,Yongquan; Liu,Ying

doi:10.3892/etm.2016.3748

Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure

Authors:
- Zhihua Fang
- Xiaoguang Yin
- Jianzhong Wang
- Na Tian
- Qiang Ao
- Yongquan Gu
- Ying Liu
View Affiliations

Affiliations: Department of Hematology, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China, Jilin Tuhua Bioengineering Company Limited, Siping, Jilin 136000, P.R. China, Department of Tissue Engineering, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China
Published online on: September 26, 2016 https://doi.org/10.3892/etm.2016.3748
Pages: 3328-3332
Copyright: © Fang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Congestive heart failure (HF) is a leading cause of morbidity and mortality worldwide. Although advances in medical therapy, mechanical support and heart transplantation have been made, almost half of all patients with HF succumb to the disease within five years of the initial diagnosis. Therefore, treatment methods need to be identified to restore the structure and function of cardiac muscle. Three patients with HF caused by ischemic cardiomyopathy received human umbilical cord‑derived mesenchymal stem cell (HUC-MSC) intravenous infusion were included in the present study. Two patients demonstrated a 65.1% increase in left ventricular ejection fraction (LVEF) at the end of 3 months, which was maintained increasing 47.8% at the end of 12 months post‑HUC-MSC intravenous infusion. LVEF of patient 1 decreased slowly in the observation period. This LVEF improvement was associated with significant improvements in the clinical parameters of the New York Heart Association class, and six-minute walk test in the coupled time. The third patient showed significant improvement in the six-minute walk test at the end of 12 months, while the other parameters did not change obviously. There were no severe adverse events during and post-HUC-MSC transplantation. During follow-up, no other immunosuppressive drugs were used. In conclusion, HUC-MSC therapy is a reasonable salvage treatment in HF. Future large-scale randomized clinical trials are likely to be designed to elucidate the efficacy of the HUC-MSC transplantation therapy on HF.

View Figures

View References

1	Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, et al: New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 35:2797–2815. 2014. View Article : Google Scholar : PubMed/NCBI
2	Hare JM, Fishman JE, Gerstenblith G, Velazquez DL DiFede, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, et al: Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 308:2369–2379. 2012. View Article : Google Scholar : PubMed/NCBI
3	Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, et al: Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 311:62–73. 2014. View Article : Google Scholar : PubMed/NCBI
4	Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, et al: Cardiovascular Cell Therapy Research Network (CCTRN): Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 307:1717–1726. 2012. View Article : Google Scholar : PubMed/NCBI
5	Mathiasen AB, Jørgensen E, Qayyum AA, Haack-Sørensen M, Ekblond A and Kastrup J: Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells in chronic ischemic heart failure (MSC-HF Trial). Am Heart J. 164:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
6	Williams AR and Hare JM: Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 109:923–940. 2011. View Article : Google Scholar : PubMed/NCBI
7	Cao Y, Gomes SA, Rangel EB, Paulino EC, Fonseca TL, Li J, Teixeira MB, Gouveia CH, Bianco AC, Kapiloff MS, et al: S-nitrosoglutathione reductase-dependent PPARγ denitrosylation participates in MSC-derived adipogenesis and osteogenesis. J Clin Invest. 125:1679–1691. 2015. View Article : Google Scholar : PubMed/NCBI
8	Premer C, Blum A, Bellio MA, Schulman IH, Hurwitz BE, Parker M, Dermarkarian CR, DiFede DL, Balkan W, Khan A, et al: Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2:467–475. 2015. View Article : Google Scholar : PubMed/NCBI
9	Castro-Manrreza ME, Mayani H, Monroy-García A, Flores-Figueroa E, Chávez-Rueda K, Legorreta-Haquet V, Santiago-Osorio E and Montesinos JJ: Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev. 23:1217–1232. 2014. View Article : Google Scholar : PubMed/NCBI
10	Qu Z, Guo S, Fang G, Cui Z and Liu Y: AKT pathway affects bone regeneration in nonunion treated with umbilical cord-derived mesenchymal stem cells. Cell Biochem Biophys. 71:1542–1551. 2014.
11	Qu Z, Guo L, Fang G, Cui Z, Guo S and Liu Y: Biological characteristics and effect of human umbilical cord mesenchymal stem cells (hUC-MSCs) grafting with blood plasma on bone regeneration in rats. Cell Biochem Biophys. 63:171–181. 2012. View Article : Google Scholar : PubMed/NCBI
12	Liu Y, Shi ZL and Zhao Z: Transplantation of human umbilical cord-derived mesenchymal stem cells improves hepatic fibrosis in rats with carbon etrachloride-induced hepatic cirrhosis. Chinese J Tissue Engineering Res. 16:1837–1840. 2012.(In Chinese).
13	Qu Z, Fang G, Cui Z and Liu Y: Cell therapy for bone nonunion: a retrospective study. Minerva Med. 106:315–321. 2015.PubMed/NCBI
14	Seth S, Bhargava B, Narang R, Ray R, Mohanty S, Gulati G, Kumar L, Airan B and Venugopal P: AIIMS Stem Cell Study Group: The ABCD (autologous bone marrow cells in dilated cardiomyopathy) trial a long-term follow-up study. J Am Coll Cardiol. 55:1643–1644. 2010. View Article : Google Scholar : PubMed/NCBI
15	Fischer-Rasokat U, Assmus B, Seeger FH, Honold J, Leistner D, Fichtlscherer S, Schächinger V, Tonn T, Martin H, Dimmeler S, et al: A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail. 2:417–423. 2009. View Article : Google Scholar : PubMed/NCBI
16	Gho JM, Kummeling GJ, Koudstaal S, Of Lorkeers SJ Jansen, Doevendans PA, Asselbergs FW and Chamuleau SA: Cell therapy, a novel remedy for dilated cardiomyopathy? A systematic review. J Card Fail. 19:494–502. 2013. View Article : Google Scholar : PubMed/NCBI